Human respiratory syncytial virus primary prevention

Human respiratory syncytial virus Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Human Respiratory Syncytial Virus from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Human respiratory syncytial virus primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Human respiratory syncytial virus primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Human respiratory syncytial virus primary prevention
CDC on Human respiratory syncytial virus primary prevention
Human respiratory syncytial virus primary prevention in the news
Blogs on Human respiratory syncytial virus primary prevention
Directions to Hospitals Treating Human respiratory syncytial virus
Risk calculators and risk factors for Human respiratory syncytial virus primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

As the virus is ubiquitous in all parts of the world, avoidance of infection is not possible.

Prevention

Epidemiologically, a vaccine would be the best answer. Unfortunately, vaccine development has been fraught with spectacular failure and with difficult obstacles. Researchers are working on a live, attenuated vaccine, but at present no vaccine exists. However, Palivizumab (brand name Synagis), a moderately effective prophylactic drug is available for infants at high risk. Palivizumab is a monoclonal antibody directed against RSV proteins. It is given by monthly injections, which are begun just prior to the RSV season and are usually continued for five months. RSV prophylaxis is indicated for infants that are premature or have either cardiac or lung disease.